Literature DB >> 17058362

[Cultural adaptation and validation of the "Fibromyalgia Impact Questionnaire"--Portuguese version].

Maria da Lapa Rosado1, José Pascoalinho Pereira, João Pedro da Fonseca, Jaime C Branco.   

Abstract

The aim of this study was to translate the Fibromyalgia Impact Questionnaire (FIQ) into Portuguese (Portugal) and to evaluate its reliability and validity by use with Portuguese--speaking patients with Fibromyalgia. After translating the FIQ into Portuguese we administered it to 68 patients with Fibromyalgia together with an informed consent, a Portuguese version of the Health Assessment Questionnaire (HAQ) and a formulary with the socio-demographic characteristics and duration of the complaints. The content validity was assessed with a panel of experts, with high consensus. In the concurrent validity, we obtained significant correlations between the FIQ first item and the HAQ [r = 0,531 (p = 0,001)]. Cronbach's alpha was 0,814, indicating an acceptable level of internal consistency. In conclusion, the Portuguese version of the FIQ is a reliable and valid instrument for measuring health status and physical functioning in Portuguese patients with Fibromyalgia. This instrument is available for use in the clinical practice.

Entities:  

Mesh:

Year:  2006        PMID: 17058362

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  2 in total

1.  Health-related quality of life in women with fibromyalgia: clinical and psychological factors associated.

Authors:  Ricardo Pereira Campos; Maria Isabel Vázquez Rodríguez; Maria Isabel Rodríguez Vázquez
Journal:  Clin Rheumatol       Date:  2011-10-07       Impact factor: 2.980

2.  A Brazilian Portuguese version of the Revised Fibromyalgia Impact Questionnaire (FIQR): a validation study.

Authors:  Eduardo S Paiva; Roberto E Heymann; Marcelo C Rezende; Milton Helfenstein; Jose Eduardo Martinez; Jose Roberto Provenza; Aline Ranzolin; Marcos Renato de Assis; Vivian D Pasqualin; Robert M Bennett
Journal:  Clin Rheumatol       Date:  2013-04-21       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.